| 000 | 01794 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515105518.0 | ||
| 264 | 0 | _c20080603 | |
| 008 | 200806s 0 0 eng d | ||
| 022 | _a0887-4476 | ||
| 024 | 7 |
_a10.1002/syn.20481 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLee, Joohyung | |
| 245 | 0 | 0 |
_aReceptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease. _h[electronic resource] |
| 260 |
_bSynapse (New York, N.Y.) _cApr 2008 |
||
| 300 |
_a310-3 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenergic Agents _xtoxicity |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aDopamine Agents _xpharmacology |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xphysiopathology |
| 650 | 0 | 4 | _aGene Expression |
| 650 | 0 | 4 | _aIn Situ Hybridization |
| 650 | 0 | 4 | _aIntracellular Signaling Peptides and Proteins |
| 650 | 0 | 4 |
_aLevodopa _xpharmacology |
| 650 | 0 | 4 |
_aMembrane Proteins _xbiosynthesis |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aOxidopamine _xtoxicity |
| 650 | 0 | 4 |
_aParkinsonian Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aRNA, Messenger _xanalysis |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aReceptor Activity-Modifying Protein 1 |
| 650 | 0 | 4 | _aReceptor Activity-Modifying Proteins |
| 700 | 1 | _aGomez-Ramirez, Jordi | |
| 700 | 1 | _aJohnston, Tom H | |
| 700 | 1 | _aVisanji, Naomi | |
| 700 | 1 | _aBrotchie, Jonathan M | |
| 773 | 0 |
_tSynapse (New York, N.Y.) _gvol. 62 _gno. 4 _gp. 310-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/syn.20481 _zAvailable from publisher's website |
| 999 |
_c17747343 _d17747343 |
||